Skip to main content
Edition No. 102 · GlobalEst. 2026
S&P 5007,416.59-1.77%Dow Jones51,608.17-1.49%Nasdaq24,509.76-2.94%FTSE 10010,788.77+0.35%DAX26,412.73+0.25%Nikkei 22558,860.43-3.90%Hang Seng23,508.17-4.27%EUR/USD1.0990-1.60%GBP/USD1.3191-1.18%Gold3,866.80-0.48%Crude Oil86.18-2.88%Bitcoin64,828.85-5.01%S&P 5007,416.59-1.77%Dow Jones51,608.17-1.49%Nasdaq24,509.76-2.94%FTSE 10010,788.77+0.35%DAX26,412.73+0.25%Nikkei 22558,860.43-3.90%Hang Seng23,508.17-4.27%EUR/USD1.0990-1.60%GBP/USD1.3191-1.18%Gold3,866.80-0.48%Crude Oil86.18-2.88%Bitcoin64,828.85-5.01%

LigaChem Biosciences Initiates Global Clinical Trial for New Gastric and Pancreatic Cancer Treatment

The experimental antibody-drug conjugate LCB02A aims to target CLDN18.2-positive tumors in a new phase 1/2 study.

By Planet Earth News Medicine Desk· Published 2026-10-29· 4 min read
Ivan S / Pexels / Pexels
PENN Explainer

Hear this story explained in 90 seconds.

South Korean biotechnology firm LigaChem Biosciences has officially begun a global phase 1/2 clinical trial for its experimental cancer treatment, LCB02A. The first patient in the study received the drug at a clinical site in North America on October 15, 2026. This milestone follows regulatory clearance from the United States Food and Drug Administration granted earlier in May. The trial is designed to evaluate the safety and effectiveness of the drug in patients with advanced solid tumors that express the CLDN18.2 protein. The study, identified as NCT07460375, plans to enroll up to 191 participants who have not responded to standard treatment options. Researchers will focus on patients with gastric, gastroesophageal junction, and pancreatic cancers. The phase 1 portion of the trial aims to determine the appropriate dosage and assess the overall tolerability of the medication. Once the safety profile is established, the phase 2 portion will measure the drug's ability to shrink tumors and improve patient outcomes. LCB02A is an antibody-drug conjugate, a type of therapy that combines a targeted antibody with a potent cell-killing agent. The drug uses the company's proprietary ConjuALL platform to attach exatecan, a topoisomerase 1 inhibitor, to an antibody that specifically seeks out CLDN18.2. This protein is frequently found on the surface of certain cancer cells, making it a strategic target for precision medicine. By delivering the toxic payload directly to these cells, the treatment aims to minimize damage to healthy tissue. While other treatments targeting CLDN18.2 exist, such as the monoclonal antibody Vyloy, LCB02A represents a different approach. Vyloy, developed by Astellas Pharma, was approved by the FDA in 2024 for use alongside chemotherapy. Unlike that antibody, LCB02A is designed to deliver a cytotoxic payload directly into the cancer cell. LigaChem Biosciences stated that it intends to develop this candidate as a potential first-line treatment option for patients. Data presented at the European Society for Medical Oncology Congress in Madrid, Spain, provided further insight into the drug's potential. In animal models, a single dose of LCB02A was shown to suppress tumor growth for approximately two months. These preclinical findings suggested that the drug could be effective even at low doses in gastric and pancreatic cancer models. The company shared these results alongside the design of the new global clinical trial. Ock Chan-young, the head of translational research at LigaChem Biosciences, emphasized the company's long-term goals for the therapy. He noted that the development strategy focuses on positioning the drug as a primary treatment rather than a secondary option. The team is currently reviewing criteria for CLDN18.2 expression to ensure the treatment reaches the most suitable patient populations. Success in the upcoming clinical phases will be critical for determining the drug's future role in oncology. The broader landscape for CLDN18.2-targeted therapies is becoming increasingly competitive. Other pharmaceutical companies, including Takeda and AstraZeneca, are also advancing their own antibody-drug conjugates through late-stage clinical trials. These developments highlight a significant shift toward using targeted biomarkers to guide treatment decisions in gastric and gastroesophageal cancers. As these trials progress, researchers hope to provide more effective alternatives for patients with limited options. Clinical trial sites are now working to recruit participants who meet the specific biomarker requirements for the study. The trial will also include a separate evaluation for patients whose disease has progressed after receiving prior CLDN18.2-targeted therapies. This design allows investigators to understand how the drug performs in different clinical scenarios. The results from this study will be essential for future regulatory submissions and potential market approval. Healthcare professionals are closely monitoring these developments as they integrate biomarker testing into standard clinical practice. Reliable testing pathways are necessary to identify which patients are eligible for these targeted therapies. As more data becomes available from global trials, the medical community expects to gain a clearer picture of how these new conjugates fit into existing treatment protocols. The ongoing research reflects a broader effort to improve survival rates for patients with aggressive gastrointestinal malignancies.

You've reached your free article limit

You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.

Already a subscriber? Sign in.

Ask the Author

Subscribers can ask the journalist a question about this story. Subscribe to ask.

Neutrality note

Auto-harvested from global news wires and presented neutrally by PENN.

Share this article

to vote

Comments

No comments yet — be the first to share your thoughts.

Related stories in Medicine